Skip to Main Content

Author Details

Lynda Coughlan
University of Maryland
2009
56
28
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38086382Viral platform engineering for targeted gene delivery to human hematopoietic stem cells.Mol Ther2024
36639569Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice.Sci Rep2023
37703367Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.Sci Adv2023
37201525Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target.Mol Ther2023
36779758Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.J Virol2023
34999208A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.Mol Ther2022
35658571Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.Microbiol Spectr2022
36426358RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine.Front Immunol2022
36042229The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.NPJ Vaccines2022
34942633Broadly neutralizing antibodies target a haemagglutinin anchor epitope.Nature2022
35092844Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.Mol Ther2022
33288923A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.Nat Med2021
33495306Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Science2021
33653892Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.mBio2021
33619476COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.Res Sq2021
33633727Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.Front Immunol2021
34914685Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.PLoS Biol2021
34851659ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.Sci Adv2021
35028623Caught in a trap: How pre-clinical studies in laboratory mice exaggerate vaccine responses.Cell Rep Med2021
34707161A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.Nat Commun2021
34671037COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.Nat Commun2021
34311574Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner.mBio2021
34278670Corrigendum: Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.Angew Chem Int Ed Engl2021
33464672Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.Angew Chem Int Ed Engl2021
32359470A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.Mol Ther2020
33073694Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.Emerg Microbes Infect2020
33182279Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.Vaccines (Basel)2020
33298562Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.Sci Transl Med2020
33096040Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.Immunity2020
32995785Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.bioRxiv2020
32910919Snatching the Crown from SARS-CoV-2.Cell Host Microbe2020
32676603Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection.bioRxiv2020
32508823Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.Front Immunol2020
30765704Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.Nat Commun2019
31934599Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.Mol Ther Methods Clin Dev2019
29367266The Novel Oncolytic Adenoviral Mutant Ad5-3ο-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.Mol Cancer Ther2018
30001520Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine.Cell Host Microbe2018
29519670Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.EBioMedicine2018
29735416Corrigendum to "Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults" [EBioMedicine 29 (2018) 146-154].EBioMedicine2018
28381574Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction <i>In Vitro</i> in the Presence of Mouse Serum.J Virol2017
27056886Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.Oncotarget2016
25560474Adenoviral vectors as novel vaccines for influenza.J Pharm Pharmacol2015
26343189Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges.Vaccines (Basel)2015
26576856Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.Sci Rep2015
23831594Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.Mol Ther2014
24617540Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.Hum Gene Ther2014
24374965Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.Mol Ther2014
24243238Genetically engineering adenoviral vectors for gene therapy.Methods Mol Biol2014
22626939Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.J Control Release2012
22708837Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.Hum Gene Ther2012
  • 1 - 50 of 56

Recommended Authors

James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 11
Chengjin Ye
Texas Biomedical Research Institute
Career Start Year 2013
Number of shared co-authors 13
Anshu P Gounder
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2012
Number of shared co-authors 4
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 11
Xuping Xie
University of Texas Medical Branch
Career Start Year 2010
Number of shared co-authors 3
James Zengel
Stanford University School of Medicine
Career Start Year 2010
Number of shared co-authors 2
Thomas J Gardner
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 5
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 2
Carolina S Ilkow
Ottawa Hospital Research Institute
Career Start Year 2006
Number of shared co-authors 0
Nicholas S Heaton
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 7
Pavlo Gilchuk
Vanderbilt University Medical Center
Career Start Year 2005
Number of shared co-authors 5
Joanna Poutou
Ottawa Hospital Research Institute
Career Start Year 2005
Number of shared co-authors 0
Lingshu Wang
National Institute of Allergy and Infectious Disease, National Institute of Health
Career Start Year 2003
Number of shared co-authors 2
Alexandra Sch??fer
University of North Carolina at Chapel Hill
Career Start Year 2003
Number of shared co-authors 5
Balaji Manicassamy
University of Iowa
Career Start Year 2002
Number of shared co-authors 10
Randy A Albrecht
Icahn School of Medicine at Mount Sinai
Career Start Year 2001
Number of shared co-authors 20
Man-Seong Park
Korea University College of Medicine
Career Start Year 2001
Number of shared co-authors 4
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 19
Gary P Kobinger
University of Texas Medical Branch
Career Start Year 1997
Number of shared co-authors 2
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 10
Boyd L Yount
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 4
Ana Fernandez-Sesma
Icahn School of Medicine at Mount Sinai
Career Start Year 1993
Number of shared co-authors 14
Ande West
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 0
Ted M Ross
Center for Vaccines and Immunology, University of Georgia
Career Start Year 1991
Number of shared co-authors 3
David B Weiner
Wistar Institute
Career Start Year 1986
Number of shared co-authors 1
Bart L Haagmans
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 2
Michael S Diamond
Washington University School of Medicine
Career Start Year 1982
Number of shared co-authors 8
Ralph S Baric
University of North Carolina
Career Start Year 1981
Number of shared co-authors 6
Yoshihiro Kawaoka
Influenza Research Institute, University of Wisconsin
Career Start Year 1979
Number of shared co-authors 9
James E Crowe
Vanderbilt University Medical Center
Career Start Year 1975
Number of shared co-authors 6

Collaborators

Adolfo Garc??a-Sastre
Icahn School of Medicine at Mount Sinai
Co-authored papers 16
Michael Schotsaert
Icahn School of Medicine at Mount Sinai
Co-authored papers 12
Raveen Rathnasinghe
Icahn School of Medicine at Mount Sinai New York
Co-authored papers 11
Peter Palese
Icahn School of Medicine at Mount Sinai
Co-authored papers 9
Christopher B Wilson
Drukier Institute for Children's Health
Co-authored papers 4
Nico van Rooijen
Co-authored papers 4
Ian A Wilson
The Scripps Research Institute, USA The Skaggs Institute for Chemical Biology
Co-authored papers 3
Melissa B Uccellini
Icahn School of Medicine at Mount Sinaigrid.59734.3c
Co-authored papers 3
Ignacio Mena
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 2
Norbert Pardi
Co-authored papers 2
David C Montefiori
Co-authored papers 2
Soner Yildiz
University of Geneva
Co-authored papers 2
Natalia A Kuzmina
University of Texas Medical Branch, USA Galveston National Laboratory
Co-authored papers 2
Teresa Aydillo
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Ajda Rojc
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 1
Dan H Barouch
Co-authored papers 1
Thomas P Zwaka
Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Carles Mart??nez-Romero
Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Jacqueline M Fabius
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 1
Kris M White
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 1
Kevan M Shokat
University of California San Francisco
Co-authored papers 1
Thomas Kehrer
Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Marco Vignuzzi
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 1
Alejandro Losada
Hospital Infantil Universitario "La Paz"
Co-authored papers 1
Marion Dejosez
Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Jyoti Batra
J. David Gladstone Institutes
Co-authored papers 1
Vladimir Vigdorovich
Center for Global Infectious Disease Research, Seattle Children's Hospital
Co-authored papers 1
Kirsten Obernier (CM4AI)
University of California San Francisco
Co-authored papers 1
Pablo Avil??s
Departamento de Toxicologia y Farmacologia Preclinica
Co-authored papers 1
Release 1.2